Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Infections with Plasmodium falciparum and Plasmodium vivax cause over 600,000 deaths
each year, concentrated in Africa and in young children, but much of the world's population …

Control measures have significantly reduced malaria morbidity and mortality in the last two
decades; however, the downward trends have stalled and have become complicated by the …

Extreme diversity of the major Plasmodium falciparum antigen, PfEMP1, poses a barrier to
identifying targets of immunity to malaria. Here, we used protein microarrays containing …

Existing control measures have significantly reduced malaria morbidity and mortality in the
last two decades, although these reductions are now stalling. Significant efforts have been …

Vaccines against infectious diseases have had great successes in the history of public
health. Major breakthroughs have occurred in the development of vaccine-based …

Much of the gain in malaria control, in terms of regional achievements in restricting
geographical spread and reducing malaria cases and deaths, can be attributed to large …

Globally, malaria continues to be an enormous public health burden, with concomitant
parasite-induced damage to the gastrointestinal (GI) barrier resulting in bacteremia …

Clinical immunity to malaria develops after repeated exposure to Plasmodium falciparum
parasites. Broadly reactive antibodies against parasite antigens expressed on the surface of …

Malaria poses a significant global health challenge, resulting in approximately 600,000
deaths each year. Individuals living in regions with endemic malaria have the potential to …